{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:25Z","timestamp":1793656525025,"version":"4.5.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03554-y","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:58:59Z","timestamp":1774335539000},"page":"2236-2253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA"],"prefix":"10.1007","volume":"43","author":[{"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla O.","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Lengil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Perciavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Hoang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"3554_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/CMAR.S510408","volume":"17","author":"U Goel","year":"2025","unstructured":"Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D. Ciltacabtagene Autoleucel for the treatment of relapsed\/refractory multiple myeloma: efficacy, safety, and place in therapy. Cancer Manag Res. 2025;17:357\u201372. https:\/\/doi.org\/10.2147\/CMAR.S510408.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"3554_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","volume":"62","author":"M Braunlin","year":"2021","unstructured":"Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data. Leuk Lymphoma. 2021;62(2):377\u201386. https:\/\/doi.org\/10.1080\/10428194.2020.1827253.","journal-title":"Leuk Lymphoma"},{"key":"3554_CR3","unstructured":"US Food & Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Accessed May\u00a022, 2025."},{"issue":"7(Suppl)","key":"3554_CR4","doi-asserted-by":"publisher","first-page":"e6102468","DOI":"10.1097\/01.HS9.0000967720.61024.68","volume":"8","author":"N Munshi","year":"2023","unstructured":"Munshi N, Martin T, Usmani S, et al. S202: CARTITUDE-1 final results: phase\u00a01b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. Hemasphere. 2023;8(7(Suppl)):e6102468.","journal-title":"Hemasphere"},{"issue":"10297","key":"3554_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene Autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase\u00a01b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"key":"3554_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/s2152-2650(23)01893-1","author":"Y Lin","year":"2023","unstructured":"Lin Y, Martin TG, Usmani S, et al. CARTITUDE-1 final results: phase\u00a01b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023. https:\/\/doi.org\/10.1016\/s2152-2650(23)01893-1.","journal-title":"J Clin Oncol"},{"issue":"25","key":"3554_CR7","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43(25):2766\u201371. https:\/\/doi.org\/10.1200\/JCO-25-00760.","journal-title":"J Clin Oncol"},{"key":"3554_CR8","unstructured":"Johnson & Johnson. CARVYKTI\u00ae is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy. https:\/\/www.jnj.com\/media-center\/press-releases\/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-u-s-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy. Accessed June 23, 2025."},{"issue":"3","key":"3554_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, et al. International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543\u201354. https:\/\/doi.org\/10.1038\/s41375-024-02482-6.","journal-title":"Leukemia"},{"issue":"1","key":"3554_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145(1):85\u201397. https:\/\/doi.org\/10.1182\/blood.2024025945.","journal-title":"Blood"},{"issue":"1","key":"3554_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41408-024-01049-z","volume":"14","author":"J Richter","year":"2024","unstructured":"Richter J. Like a bridge over troubled water: keeping the myeloma down en route to CAR-T. Blood Cancer J. 2024;14(1):64. https:\/\/doi.org\/10.1038\/s41408-024-01049-z.","journal-title":"Blood Cancer J"},{"issue":"1","key":"3554_CR12","doi-asserted-by":"publisher","first-page":"e70070","DOI":"10.1002\/hem3.70070","volume":"9","author":"M Merz","year":"2025","unstructured":"Merz M, Albici AM, von Tresckow B, et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study. Hemasphere. 2025;9(1):e70070. https:\/\/doi.org\/10.1002\/hem3.70070.","journal-title":"Hemasphere"},{"issue":"6","key":"3554_CR13","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1007\/s12325-022-02087-4","volume":"39","author":"JJ Jalbert","year":"2022","unstructured":"Jalbert JJ, Wu N, Chen CI, Ambati S, Ge W, Arnason JE. Real-world treatment patterns after CD19-directed CAR T\u00a0cell therapy among patients with diffuse large B\u00a0cell lymphoma. Adv Ther. 2022;39(6):2630\u201340. https:\/\/doi.org\/10.1007\/s12325-022-02087-4.","journal-title":"Adv Ther"},{"key":"3554_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/CCI.19.00094","volume":"4","author":"BG Patel","year":"2020","unstructured":"Patel BG, Luo S, Wildes TM, Sanfilippo KM. Frailty in older adults with multiple myeloma: a study of US veterans. JCO Clin Cancer Inform. 2020;4:117\u201327. https:\/\/doi.org\/10.1200\/CCI.19.00094.","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"3554_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"issue":"13","key":"3554_CR16","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen DK, Peres LC, Dima D, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43(13):1597\u2013609. https:\/\/doi.org\/10.1200\/JCO-24-01730.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3554_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136. https:\/\/doi.org\/10.1038\/s41375-022-01531-2.","journal-title":"Leukemia"},{"issue":"9","key":"3554_CR18","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375. https:\/\/doi.org\/10.1038\/s41375-019-0435-7.","journal-title":"Leukemia"},{"key":"3554_CR19","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/S2152-2650(24)01908-6","volume":"24","author":"S Anguille","year":"2024","unstructured":"Anguille S, Leleu X, Gatt M, et al. Effectiveness of bridging therapy corresponds to improved outcomes after receiving CAR-T therapy in the phase\u00a03 CARTITUDE-4 study of patients with relapsed lenalidomide-refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:S42\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3554_CR20","volume-title":"The EBMT\/EHA CAR-T\u00a0cell handbook","author":"S Manier","year":"2022","unstructured":"Manier S, Jurczyszyn A, Vesole DH. Bridging chemotherapy: multiple myeloma. In: Kroger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT\/EHA CAR-T\u00a0cell handbook. Cham: Springer; 2022."},{"issue":"1","key":"3554_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14(1):63. https:\/\/doi.org\/10.1038\/s41408-024-00993-0.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3554_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.46989\/001c.116261","volume":"6","author":"ST Bhaskar","year":"2024","unstructured":"Bhaskar ST, Dholaria B, Savani BN, Oluwole O. The evolving role of bridging therapy during CAR-T therapy. Clin Hematol Int. 2024;6(3):9\u201316. https:\/\/doi.org\/10.46989\/001c.116261.","journal-title":"Clin Hematol Int"},{"key":"3554_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.08.005","author":"S Ailawadhi","year":"2025","unstructured":"Ailawadhi S, Anderson LD Jr, Dhakal B, Shune L, Sborov D, Hansen DK. Optimizing selection of bridging therapies prior to CAR-T therapy administration for multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.08.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"3554_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1182\/blood-2024-202017","volume":"144","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Akhtar OS, Cowan AJ, et al. Talquetamab bridging: paving the way to B-cell maturation antigen (BCMA) CAR-T\u00a0cell therapy in relapsed\/refractory multiple myeloma (RRMM). Blood. 2024;144(Supplement 1):931.","journal-title":"Blood"},{"key":"3554_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029773","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Akhtar OS, Fandrei D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T\u00a0cell therapy. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2025029773.","journal-title":"Blood"},{"issue":"4","key":"3554_CR26","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021;11(4):1121\u201331.","journal-title":"Am J Cancer Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03554-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:37:50Z","timestamp":1778229470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03554-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3554"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03554-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sikander Ailawadhi has provided consultancy for GSK, Sanofi, Bristol-Myers Squibb, Takeda, Beigene, Regeneron, Johnson & Johnson, Cellectar, Amgen, and Pharmacyclics; and received research funding from GSK, Bristol-Myers Squibb, Johnson & Johnson, Ascentage, AbbVie, Xencor, Amgen, and Pharmacyclics. Doris K. Hansen has provided consultancy for Bristol-Myers Squibb, Janssen, Pfizer, AstraZeneca, Kite Pharma\/Gilead Sciences, and Karyopharm; and received research funding from Bristol-Myers Squibb, Johnson & Johnson, Adaptive Biotechnologies, and Karyopharm. Binod Dhakal has provided consultancy for Genentech and Pfizer; received research funding from Johnson & Johnson, Bristol-Myers Squibb, Acrellx, Sanofi, Carsgen, and C4 Therapeutics; received honoraria from Johnson & Johnson, Bristol-Myers Squibb, Karyopharm, Genentech, and Pfizer; and participated in a Speakers Bureau for Johnson & Johnson and Pfizer. Leyla O. Shune has provided consultancy for Bristol-Myers Squibb and Johnson & Johnson. Larry D. Anderson Jr has provided consultancy to Bristol-Myers Squibb, Celgene, GlaxoSmithKline, AbbVie, Johnson & Johnson, Prothena, Sanofi, Beigene, Cellectar Biosciences, and Amgen; received research funding from Bristol-Myers Squibb, Celgene, AbbVie, Johnson & Johnson, and Cellectar Biosciences; received honoraria from Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Johnson & Johnson, Prothena, Sanofi, Pfizer, Beigene, Cellectar Biosciences, and Amgen; and participated in a Board of Directors or Advisory Committee for Celgene, GlaxoSmithKline, AbbVie, Karyopharm, Johnson & Johnson, Prothena, Sanofi, Pfizer, Beigene, Cellectar Biosciences, and Amgen. Kevin C. DeBraganca, Tamar Lengil, Victoria Alegria, Jack Hoang Lu, Elizabeth Sacchi, Seina Lee, Stephen Huo, Todd Bixby, and Zaina P. Qureshi are employees of Johnson & Johnson, and own stock\/stock options in Johnson & Johnson. Matthew Perciavalle is an employee of Legend Biotech and owns stock\/stock options in Legend Biotech. Bruno Emond is an employee of Analysis Group ULC, a consulting company that has provided paid consulting services to Johnson & Johnson, which along with Legend Biotech USA Inc., funded the development and conduct of this study and manuscript. Douglas W. Sborov has provided consultancy for AbbVie, Arcellx, AstraZeneca, Bristol Myers Squibb, Caribou, Genentech, GlaxoSmithKline, Johnson & Johnson, Opna Bio, Pfizer, Regeneron, Legend Biotech, and Sanofi; received research funding from Johnson & Johnson, Pfizer, and Regeneron.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was considered exempt from review by an institutional review board as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act, specifically, 45 CFR \u00a7 164.514. The authors had permission to access and use the KRD+ database for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}